Minimal residual disease negativity predicts time to next treatment in multiple myeloma
by Elana GotkineFor patients with multiple myeloma (MM), minimal residual disease (MRD) negativity determined using next-generation sequencing (NGS) is predictive of longer time to next treatment (TTN
Updated on: January 22,2024
17

Minimal residual disease negativity predicts time to next treatment in multiple myeloma
by Elana GotkineFor patients with multiple myeloma (MM), minimal residual disease (MRD) negativity determined using next-generation sequencing (NGS) is predictive of longer time to next treatment (TTN
Updated on:January 22,2024
17
